PriceTargets.com logo

TELA Bio - TELA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.67
  • Forecasted Upside: 207.81%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.44 As of 04/23/2024 12:40 PM ET
▼ -0.13 (-2.84%)

This chart shows the closing price for TELA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TELA Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TELA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TELA

Analyst Price Target is $13.67
▲ +207.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for TELA Bio in the last 3 months. The average price target is $13.67, with a high forecast of $15.00 and a low forecast of $12.00. The average price target represents a 207.81% upside from the last price of $4.44.

This chart shows the closing price for TELA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in TELA Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$15.00Low
3/22/2024Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $12.00Low
12/27/2023Lake Street CapitalReiterated RatingBuy ➝ Buy$14.00Low
11/10/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$20.00 ➝ $15.00Low
3/28/2023Canaccord Genuity GroupReiterated RatingBuy$15.00Low
3/22/2023JMP SecuritiesReiterated RatingMarket Outperform$20.00Low
11/10/2022JMP SecuritiesLower TargetMarket Outperform$22.00 ➝ $20.00Low
11/10/2022Piper SandlerLower TargetOverweight$20.00 ➝ $15.00Low
6/1/2022JMP SecuritiesReiterated RatingBuy$22.00High
5/31/2022Lake Street CapitalInitiated CoverageBuy$17.00High
3/22/2022JMP SecuritiesReiterated RatingBuy$22.00High
11/11/2020Piper SandlerBoost TargetOverweight$17.00 ➝ $20.00Low
8/12/2020Piper SandlerBoost TargetOverweight$14.00 ➝ $17.00High
7/9/2020Jefferies Financial GroupBoost TargetBuy$17.00 ➝ $20.00Medium
6/18/2020JMP SecuritiesBoost TargetOutperform$20.00 ➝ $24.00High
5/13/2020JMP SecuritiesLower TargetMarket Outperform$22.00 ➝ $20.00High
1/10/2020Piper SandlerReiterated RatingBuy$17.00Medium
12/3/2019Jefferies Financial GroupInitiated CoverageBuy$23.00Medium
12/3/2019JMP SecuritiesInitiated CoverageOutperform$22.00High
12/3/2019Piper Sandler CompaniesInitiated CoverageOverweight$17.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

TELA Bio logo
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $4.44
Low: $4.43
High: $4.63

50 Day Range

MA: $5.87
Low: $4.57
High: $7.36

52 Week Range

Now: $4.44
Low: $4.23
High: $11.26

Volume

35,509 shs

Average Volume

134,389 shs

Market Capitalization

$109.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of TELA Bio?

The following Wall Street sell-side analysts have issued reports on TELA Bio in the last twelve months: JMP Securities, Lake Street Capital, and Piper Sandler.
View the latest analyst ratings for TELA.

What is the current price target for TELA Bio?

3 Wall Street analysts have set twelve-month price targets for TELA Bio in the last year. Their average twelve-month price target is $13.67, suggesting a possible upside of 199.1%. JMP Securities has the highest price target set, predicting TELA will reach $15.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $12.00 for TELA Bio in the next year.
View the latest price targets for TELA.

What is the current consensus analyst rating for TELA Bio?

TELA Bio currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TELA will outperform the market and that investors should add to their positions of TELA Bio.
View the latest ratings for TELA.

What other companies compete with TELA Bio?

Other companies that are similar to TELA Bio include Neuronetics, Delcath Systems, Allurion Technologies, KORU Medical Systems and BlueRiver Acquisition. Learn More about companies similar to TELA Bio.

How do I contact TELA Bio's investor relations team?

TELA Bio's physical mailing address is 1 GREAT VALLEY PARKWAY SUITE 24, MALVERN PA, 19355. The company's listed phone number is 484-320-2930 and its investor relations email address is [email protected]. The official website for TELA Bio is www.telabio.com. Learn More about contacing TELA Bio investor relations.